As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like ...

Adbry is used to treat moderate to severe atopic dermatitis (eczema ... more about how Adbry and Dupixent compare. They can also help determine whether one of these treatments may be right ...

Dupixent is already approved in the US for a variety of indications, going back to eczema in 2017 (and most recently for the treatment of the rare skin condition prurigo nodularis), but its ...

Treatment should be stopped after 16 weeks if there hasn’t been an improvement of 50% or more in symptoms – measured using the Eczema Area ... s biologic therapy Dupixent (dupilumab), which ...

SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a ...

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Over 10% of people in the United States have some form of eczema and nearly one-fifth experience more than one eczema diagnosis, according to new research from the National Eczema Association.

The sparsity of mid-to-late stage prospects in atopic dermatitis (AD, or eczema) – which has proved an especially challenging indication – plus some newsmaking fizzles in the space have caused ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.

“Since certain topicals can exacerbate perioral dermatitis and treatments are all by prescription, medical care is recommended.” In rare cases, the rash may also appear around the genital ...